Theranexus SA Asset Resilience Ratio

Latest as of December 2025: 66.61%

Theranexus SA asset resilience ratio. Theranexus SA (ALTHX) has an Asset Resilience Ratio of 66.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALTHX defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€7.02 Million
≈ $8.21 Million USD Cash + Short-term Investments

Total Assets

€10.54 Million
≈ $12.33 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Theranexus SA (2015–2025)

Asset resilience ratio of Theranexus SA from 2015 to 2025. This chart shows how Theranexus SA's Asset Resilience Ratio has changed over time. Read Theranexus SA debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Theranexus SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Theranexus SA balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €7.02 Million 66.61%
Total Liquid Assets €7.02 Million 66.61%

Asset Resilience Insights

  • Very High Liquidity: Theranexus SA maintains exceptional liquid asset reserves at 66.61% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Theranexus SA Industry Peers by Asset Resilience Ratio

Compare Theranexus SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

Theranexus SA Asset Resilience Ratio by Year (2015–2025)

Theranexus SA asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Theranexus SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 66.61% €7.02 Million
≈ $8.21 Million
€10.54 Million
≈ $12.33 Million
+53.12pp
2024-12-31 13.49% €504.56K
≈ $589.88K
€3.74 Million
≈ $4.37 Million
-69.47pp
2021-12-31 82.97% €14.01 Million
≈ $16.38 Million
€16.89 Million
≈ $19.75 Million
+54.34pp
2020-12-31 28.63% €5.00 Million
≈ $5.85 Million
€17.47 Million
≈ $20.42 Million
-49.79pp
2019-12-31 78.42% €12.05 Million
≈ $14.09 Million
€15.37 Million
≈ $17.97 Million
-6.65pp
2018-12-31 85.07% €16.03 Million
≈ $18.75 Million
€18.85 Million
≈ $22.04 Million
+72.96pp
2016-12-31 12.11% €348.87K
≈ $407.86K
€2.88 Million
≈ $3.37 Million
-39.08pp
2015-12-31 51.19% €1.40 Million
≈ $1.63 Million
€2.73 Million
≈ $3.19 Million
--
pp = percentage points

About Theranexus SA

PA:ALTHX France Biotechnology
Market Cap
$56.14 Million
€48.02 Million EUR
Market Cap Rank
#21889 Global
#343 in France
Share Price
€3.33
Change (1 day)
+0.45%
52-Week Range
€1.57 - €4.59
All Time High
€22.70
About

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company… Read more